BioCentury | May 4, 2020
Product Development

Investors see little value in remaining Newron programs following Rett syndrome failure

The failure of Newron’s sarizotan in Rett syndrome leaves the company with two pipeline programs, but its valuation is now trading near its cash position -- a sign that investors see little value in what...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Extra | May 28, 2019
Company News

May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more

Viela partners with Hansoh on mAb for rare CNS disorder in China  Viela Bio Inc. (Gaithersburg, Md.) granted Hansoh Pharmaceutical Group Co. Ltd. (Lianyungang, China) rights to develop and commercialize Viela's humanized anti-CD19 mAb inebilizumab...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BC Week In Review | Feb 9, 2018
Clinical News

Eisai, Meiji Seika's safinamide meets in Phase II/III for PD

Eisai Co. Ltd. (Tokyo:4523) and Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) reported preliminary data from a Phase II/III trial in about 410 Parkinson's disease patients with wearing-off phenomenon showing that once-daily 50 and 100...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Sep 29, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

On Sept. 26, several biotechs announced public financing, including follow-ons from Kadmon Holdings Inc. (NYSE:KDMN) and TherapeuticsMD Inc. (NYSE-M:TXMD). Kadmon raised $80 million through the sale of 26.8 million shares at $3 in a bumped-up...
BC Extra | Sep 27, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

On Tuesday, several biotechs announced public financing, including follow-ons from Kadmon Holdings Inc. (NYSE:KDMN) and TherapeuticsMD Inc. (NYSE-M:TXMD). Kadmon raised $72 million through the sale of 24 million shares at $3 in a follow-on and...
BC Week In Review | May 24, 2017
Clinical News

Newron expands enrollment in Phase II/III for Rett syndrome

Newron Pharmaceuticals S.p.A. (SIX:NWRN) expanded enrollment to include patients with Rett syndrome ages ≥6 in the double-blind, placebo-controlled, international Phase II/III STARS trial evaluating once-daily 10 and 20 mg sarizotan for 24 weeks. The trial...
Items per page:
1 - 10 of 237
BioCentury | May 4, 2020
Product Development

Investors see little value in remaining Newron programs following Rett syndrome failure

The failure of Newron’s sarizotan in Rett syndrome leaves the company with two pipeline programs, but its valuation is now trading near its cash position -- a sign that investors see little value in what...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Extra | May 28, 2019
Company News

May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more

Viela partners with Hansoh on mAb for rare CNS disorder in China  Viela Bio Inc. (Gaithersburg, Md.) granted Hansoh Pharmaceutical Group Co. Ltd. (Lianyungang, China) rights to develop and commercialize Viela's humanized anti-CD19 mAb inebilizumab...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BC Week In Review | Feb 9, 2018
Clinical News

Eisai, Meiji Seika's safinamide meets in Phase II/III for PD

Eisai Co. Ltd. (Tokyo:4523) and Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) reported preliminary data from a Phase II/III trial in about 410 Parkinson's disease patients with wearing-off phenomenon showing that once-daily 50 and 100...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Sep 29, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

On Sept. 26, several biotechs announced public financing, including follow-ons from Kadmon Holdings Inc. (NYSE:KDMN) and TherapeuticsMD Inc. (NYSE-M:TXMD). Kadmon raised $80 million through the sale of 26.8 million shares at $3 in a bumped-up...
BC Extra | Sep 27, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

On Tuesday, several biotechs announced public financing, including follow-ons from Kadmon Holdings Inc. (NYSE:KDMN) and TherapeuticsMD Inc. (NYSE-M:TXMD). Kadmon raised $72 million through the sale of 24 million shares at $3 in a follow-on and...
BC Week In Review | May 24, 2017
Clinical News

Newron expands enrollment in Phase II/III for Rett syndrome

Newron Pharmaceuticals S.p.A. (SIX:NWRN) expanded enrollment to include patients with Rett syndrome ages ≥6 in the double-blind, placebo-controlled, international Phase II/III STARS trial evaluating once-daily 10 and 20 mg sarizotan for 24 weeks. The trial...
Items per page:
1 - 10 of 237